Thursday, 25 June 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 25 June 2026
Vivacity
Vivacity
Latest News
Lilly says 'No' to Aussie drug launch

PBS pricing is so low that Eli Lilly has decided not to bring this game-changing drug to Australia in the foreseeable future, delivering another blow to the nation's failing reimbursement system.

Companies eye monster market
With a trump card in the form of a superior safety profile, this partnership is ready to crack a lucrative market
TODAY
Aussie drug heads to LA
A promising new cancer treatment developed by Aussie researchers has been acquired for an undisclosed price
TODAY
Most Popular
Another Country Leader departs
After just seven months in the top job and less than a year since resigning from his previous role, this ANZ leader is moving on
24 June
Second ANZ Leader resigns in 24 hours
A local GM has decided to seek other opportunities rather than take up an expanded role in a restructured company
24 June
Burnout stories from the frontline
Australian pharma professionals have lifted the lid on workload and burnout within companies with an expert revealing how to lighten the load
24 June
Which Aussie Drs love seeing Reps?
Survey reveals which healthcare practitioners most prefer to get medical information from pharma reps, and by how much
23 June
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (19)

Access & Reimbursement (2)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (6)

Executive Roles (7)

Other (11)

More News
July PBS wait list swells to 18
Eighteen submissions recommended by the PBAC have progressed to the final stage ahead of a possible PBS listing next month
24 June
Dept preps for more broad listings
Govt issues guidelines for pharmas wanting to win a broad listing for their anti-cancer drug but there's a catch with pricing
24 June
AbbVie pays big for major market
Pharma drops $15.6 billion for a challenger to Dupixent in atopic dermatitis, which it hopes will become a mega-blockbuster
24 June
Mega pays are not just for CEOs
You don't have to be CEO to earn a whopper salary - 10 scientists and doctors in Big Pharma have hit the jackpot with earnings of more than $AU14M last year
23 June
ASCO Breakthrough hits Singapore
Conference kicks off in Singapore for the first time with oncologists exploring region-focused treatments, and how to expand personalisation
23 June
Company beefs up Access role
With market access an ever-growing pain point for industry, one company has broadened this function. See who's leading the new team
23 June
Funding failures hurt productivity
MA report highlights the ripple effect of delayed access to innovative medicines, extending far beyond health outcomes
23 June
Another pharma cuts Aussie jobs
Yet another Big Pharma has downsized its Australian workforce as part of a global restructure designed to realign resources
22 June
Novo hit with $105M ransom demand
The company's biggest secrets - including "confidential recipes" for its top drugs appear to be for sale on the Dark Web after the company refused hackers' demands
22 June
Industry body unveils new name
Entering its second decade, this well-known industry body has announced new branding, including a 'bold' new name
22 June
Price moves get mixed PBAC result
The PBAC agreed with two price adjustments and knocked back a third at its May Intracycle meeting. See who missed out
22 June
Pfizer's $53M drug under threat
TGA approves first generic of this big earning drug as well as a medicine accepted for review more than two years ago
22 June Approvals Action
TGA flooded with new drug labels
Australia's regulator has accepted 18 new indication applications for evaluation, with new cancer labels making up more than half the list
19 June
PBAC agenda tops 60 submissions
Five submissions added and one moved to a future meeting in version 4 of the PBAC's July agenda
19 June
PiF Advertise
PiF Advertise
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe